Istituto di Biostrutture e Bioimmagini-CNR, Napoli, Italy Fondazione SDN-IRCCS, Naples, Italy Diagnostic Imaging Department, University Federico II, Naples, Italy Hematology Department, University Federico II, Naples, Italy
References Riferimenti: Malpas, J. S., Caroll, J. J., (1995) Myeloma: Biology and Management, Myeloma: clinical presentation and diagnosis, pp. 169-190. , eds, New York, NY: Oxford University Press
Angtuaco, E. J., Fassas, A. B., Walker, R., Sethi, R., Barlogie, B., Multiple myeloma: Clinical review and diagnostic imaging (2004) Radiology, 231, pp. 11-23
Durie, B. G., Salmon, S. E., A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival (1975) Cancer, 36, pp. 842-854
Durie, B. G., Waxman, A. D., D'Agnolo, A., Williams, C. M., Whole-body 18F-FDG PET identifies high-risk myeloma (2002) J Nucl Med, 43, pp. 1457-1463
Smith, A., Wisloff, F., Samson, D., Myeloma Forum UK
Nordic Myeloma Study Group. British Committee for Standards in Haematology: Guidelines on the diagnosis and management of multiple myeloma 2005 (2006) Br J Haematol, 132, pp. 410-451
Durie, B. G., The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system (2006) Eur J Cancer, 42, pp. 1539-1543
D'Sa, S., Abildgaard, N., Tighe, J., Shaw, P., Hall-Craggs, M., Guidelines for the use of imaging in the management of myeloma (2007) Br J Haematol, 137, pp. 49-63
Zamagni, E., Nanni, C., Patriarca, F., A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma (2007) Haematologica, 92, pp. 50-55
Mulligan, M. E., Badros, A. Z., PET/CT and MR imaging in myeloma (2007) Skeletal Radiol, 36, pp. 5-16
Beyer 3rd, R. J., Mulligan, M. E., Smith, S. E., Line, B. R., Badros, A. Z., Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma (2006) Skeletal Radiol, 35, pp. 632-640
Tirovola, E. B., Biassoni, L., Britton, K. E., Kaleva, N., Kouykin, V., Malpas, J. S., The use of 99mTc-MIBI scanning in multiple myeloma (1996) Br J Cancer, 74, pp. 1815-1820
el-Shirbiny, A. M., Yeung, H., Imbriaco, M., Michaeli, J., Macapinlac, H., Larson, S. M., Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma (1997) J Nucl Med, 38, pp. 1208-1210
Pace L, Catalano L, Pinto A, et al. M. Different patterns of technetium-99m sestamibi uptake in multiple myeloma. Eur J Nucl Med. 1998
25: 714-720Catalano, L., Pace, L., Califano, C., Detection of focal myeloma lesions by technetium-99m-sestamibi scintigraphy (1999) Haematologica, 84, pp. 119-124
Fonti, R., Del Vecchio, S., Zannetti, A., Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma (2001) Eur J Nucl Med, 28, pp. 214-220
Mileshkin, L., Blum, R., Seymour, J. F., Patrikeos, A., Hicks, R. J., Prince, H. M., A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma (2004) Eur J Haematol, 72, pp. 32-37
Pace, L., Catalano, L., Del Vecchio, S., Washout of (99mTc) sestamibi in predicting response to chemotherapy in patients with multiple myeloma (2005) Q J Nucl Med Mol Imaging, 49, pp. 281-285
Hung, G. U., Tsai, C. C., Tsai, S. C., Lin, W. Y., Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma (2005) Anticancer Res, 25, pp. 4737-4741
Martin, M. G., Romero Colas, M. S., Dourdil Sahun, M. V., Olave, P., Alba, P. R., Banzo, J. B., Baseline Tc99-MIBI scanning predicts survival in multiple myeloma and helps to differentiate this disease from monoclonal gammopathy of unknown significance (2005) Haematologica, 90, pp. 1141-1143
Nandurkar, D., Kalff, V., Turlakow, A., Spencer, A., Bailey, M. J., Kelly, M. J., Focal MIBI uptake is a better indicator of active myeloma than diffuse uptake (2006) Eur J Haematol, 76, pp. 141-146
Mele, A., Offidani, M., Visani, G., Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: A multicentre study on 397 scans (2007) Br J Haematol, 136, pp. 729-735
Erten, N., Saka, B., Berberoglu, K., Technetium-99m 2-methoxy- isobutylisonitrile uptake scintigraphy in detection of the bone marrow infiltration in multiple myeloma: Correlation with MRI and other prognostic factors (2007) Ann Hematol, 86, pp. 805-813
Schmidt, G. P., Schoenberg, S. O., Reiser, M. F., Baur-Melnyk, A., Whole-body MR imaging of bone marrow (2005) Eur J Radiol, 55, pp. 33-40
Lucignani, G., Bone and marrow imaging: Do we know what we see and do we see what we want to know? (2007) Eur J Nucl Med Mol Imaging, 34, pp. 1123-1126
Durie, B. G., Kyle, R. A., Belch, A., Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation (2003) Hematol J, 4, pp. 379-398
Bredella, M. A., Steinbach, L., Caputo, G., Segall, G., Hawkins, R., Value of FDG PET in the assessment of patients with multiple myeloma (2005) AJR, 184, pp. 1199-1204
Jadvar, H., Conti, P. S., Diagnostic utility of FDG PET in multiple myeloma (2002) Skeletal Radiol, 31, pp. 690-694
Nanni, C., Zamagni, E., Farsad, M., Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: Preliminary results (2006) Eur J Nucl Med Mol Imaging, 33, pp. 525-531
Schirrmeister, H., Buck, A. K., Bergmann, L., Reske, S. N., Bommer, M., Positron emission tomography (PET) for staging of solitary plasmacytoma (2003) Cancer Biother Radiopharm, 18, pp. 841-845
Moulopoulos, L. A., Gika, D., Anagnostopoulos, A., Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma (2005) Ann Oncol, 16, pp. 1824-1828
Baur-Melnyk, A., Buhmann, S., Durr, H. R., Reiser, M., Role of MRI for the diagnosis and prognosis of multiple myeloma (2005) Eur J Radiol, 55, pp. 56-63
Lecouvet, F. E., Malghem, J., Michaux, L., Skeletal survey in advanced multiple myeloma: Radiographic versus MR imaging survey (1999) Br J Haematol, 106, pp. 35-39
Johnston, C., Brennan, S., Ford, S., Eustace, S., Whole body MR imaging: Applications in oncology (2006) Eur J Surg Oncol, 32, pp. 239-246
Malpas, J.S., Caroll, J.J., (1995) Myeloma: Biology and Management, Myeloma: clinical presentation and diagnosis, pp. 169-190. , eds, New York, NY: Oxford University Press
Angtuaco, E.J., Fassas, A.B., Walker, R., Sethi, R., Barlogie, B., Multiple myeloma: Clinical review and diagnostic imaging (2004) Radiology, 231, pp. 11-23
Durie, B.G., Salmon, S.E., A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival (1975) Cancer, 36, pp. 842-854
Durie, B.G., Waxman, A.D., D'Agnolo, A., Williams, C.M., Whole-body 18F-FDG PET identifies high-risk myeloma (2002) J Nucl Med, 43, pp. 1457-1463
Durie, B.G., The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system (2006) Eur J Cancer, 42, pp. 1539-1543
Mulligan, M.E., Badros, A.Z., PET/CT and MR imaging in myeloma (2007) Skeletal Radiol, 36, pp. 5-16
Beyer 3rd, R.J., Mulligan, M.E., Smith, S.E., Line, B.R., Badros, A.Z., Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma (2006) Skeletal Radiol, 35, pp. 632-640
Tirovola, E.B., Biassoni, L., Britton, K.E., Kaleva, N., Kouykin, V., Malpas, J.S., The use of 99mTc-MIBI scanning in multiple myeloma (1996) Br J Cancer, 74, pp. 1815-1820
el-Shirbiny, A.M., Yeung, H., Imbriaco, M., Michaeli, J., Macapinlac, H., Larson, S.M., Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma (1997) J Nucl Med, 38, pp. 1208-1210
25:714-720Catalano, L., Pace, L., Califano, C., Detection of focal myeloma lesions by technetium-99m-sestamibi scintigraphy (1999) Haematologica, 84, pp. 119-124
Hung, G.U., Tsai, C.C., Tsai, S.C., Lin, W.Y., Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma (2005) Anticancer Res, 25, pp. 4737-4741
Martin, M.G., Romero Colas, M.S., Dourdil Sahun, M.V., Olave, P., Alba, P.R., Banzo, J.B., Baseline Tc99-MIBI scanning predicts survival in multiple myeloma and helps to differentiate this disease from monoclonal gammopathy of unknown significance (2005) Haematologica, 90, pp. 1141-1143
Schmidt, G.P., Schoenberg, S.O., Reiser, M.F., Baur-Melnyk, A., Whole-body MR imaging of bone marrow (2005) Eur J Radiol, 55, pp. 33-40
Durie, B.G., Kyle, R.A., Belch, A., Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation (2003) Hematol J, 4, pp. 379-398
Bredella, M.A., Steinbach, L., Caputo, G., Segall, G., Hawkins, R., Value of FDG PET in the assessment of patients with multiple myeloma (2005) AJR, 184, pp. 1199-1204
Moulopoulos, L.A., Gika, D., Anagnostopoulos, A., Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma (2005) Ann Oncol, 16, pp. 1824-1828
Lecouvet, F.E., Malghem, J., Michaux, L., Skeletal survey in advanced multiple myeloma: Radiographic versus MR imaging survey (1999) Br J Haematol, 106, pp. 35-39
F-18-FDG PET/CT, Tc-99m-MIBI, and MRI in evaluation of patients with multiple myeloma
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(551 visite) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 DettagliEsporta in BibTeXEsporta in EndNote
273 Records (240 escludendo Abstract e Conferenze). Impact factor totale: 824.829 (714.289 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 941.079 (813.99 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Marco Comerci on in data Sunday 12 July 2020, 13:15:03 450 views visite. Last view on Ultima visita in data Friday 26 February 2021, 1:02:41